Department of Clinical Sciences in Malmö, Center for Primary Health Care Research, Lund University, Malmö, Sweden.
Department of Internal Medicine, Halland Hospital Halmstad, Halmstad, Sweden.
J Intern Med. 2023 Feb;293(2):184-199. doi: 10.1111/joim.13570. Epub 2022 Oct 3.
Data on unrecognized liver cirrhosis in patients with hepatocellular carcinoma (HCC) are derived mainly from cohorts with a risk of selection bias.
In a population-based cohort study we aimed to determine the proportion, characteristics, and prognosis of HCC in patients with unrecognized cirrhosis.
Using the Swedish quality register for liver cancer and other nationwide registers, we identified all adults with HCC in Sweden between 2012 and 2018 (n = 3,473).
The final study cohort comprised 2670 patients with established cirrhosis, of which 1033 (39%) had unrecognized cirrhosis at HCC diagnosis. These patients were more often male, older, and had larger tumors, multinodular cancer, portal vein thrombosis, and extrahepatic metastasis compared to patients with known cirrhosis with HCC and under surveillance (34%). Compared to surveilled patients, those with unrecognized cirrhosis had worse median survival (0.89 years, 95% confidence interval [CI] = 0.78-1.01 vs. 3.79 years, 95%CI = 3.19-4.39), and an adjusted hazard ratio of 2.36 (95%CI = 2.09-2.66). Patients with cirrhosis but not under surveillance (27%) and patients with unrecognized cirrhosis had similar characteristics, such as equal proportions diagnosed at late stage (79%).
Cirrhosis is often not recognized in patients with HCC. Unrecognized cirrhosis is associated with more advanced HCC at diagnosis and a worse prognosis. More efforts are needed to diagnose cirrhosis at an earlier stage.
关于肝细胞癌 (HCC) 患者中未被识别的肝硬化的数据主要来自存在选择偏倚风险的队列。
在一项基于人群的队列研究中,我们旨在确定未被识别的肝硬化患者中 HCC 的比例、特征和预后。
我们使用瑞典肝癌质量登记处和其他全国性登记处,确定了 2012 年至 2018 年期间瑞典所有患有 HCC 的成年人(n=3473)。
最终的研究队列包括 2670 例已确诊肝硬化的患者,其中 1033 例(39%)在 HCC 诊断时患有未被识别的肝硬化。与接受 HCC 监测的已知肝硬化患者相比,这些患者更常为男性、年龄更大、肿瘤更大、多结节性癌症、门静脉血栓形成和肝外转移(34%)。与接受监测的患者相比,未被识别的肝硬化患者的中位生存期更差(0.89 年,95%CI=0.78-1.01 与 3.79 年,95%CI=3.19-4.39),调整后的危险比为 2.36(95%CI=2.09-2.66)。未接受监测的肝硬化患者(27%)和未被识别的肝硬化患者具有相似的特征,例如同样比例的患者被诊断为晚期(79%)。
肝硬化在 HCC 患者中经常未被识别。未被识别的肝硬化与诊断时更晚期的 HCC 相关,且预后更差。需要做出更多努力来更早地诊断肝硬化。